Positive Patient Stories™

Investor Overview

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.65
Change (%) Stock is Down 0.15 (1.39%)
Volume1,317,256
Data as of 06/22/18 4:00 p.m. ET

Latest News

06/20/18
Paratek Announces FDA Advisory Committee Date for Omadacycline
06/11/18
Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018
06/07/18
Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018
06/01/18
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.